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BRIEF REPORT
Excitatory and Inhibitory Brain Metabolites as Targets of Motor Cortex
Transcranial Direct Current Stimulation Therapy and Predictors
of Its Efficacy in Fibromyalgia
Bradley R. Foerster,1 Thiago D. Nascimento,2 Misty DeBoer,2 MaryCatherine A. Bender,2 Indie C. Rice,2
Dennis Q. Truong,3 Marom Bikson,3 Daniel J. Clauw,2 Jon-Kar Zubieta,2 Richard E. Harris,2 and
Alexandre F. DaSilva2
Objective. Transcranial direct current stimula-
tion (tDCS) has been shown to improve pain symptoms
in fibromyalgia (FM), a central pain syndrome whose
underlying mechanisms are not well understood. This
study was undertaken to explore the neurochemical
action of tDCS in the brain of patients with FM, using
proton magnetic resonance spectroscopy (1H-MRS).
Methods. Twelve patients with FM underwent
sham tDCS over the left motor cortex (anode place-
ment) and contralateral supraorbital cortex (cathode
placement) for 5 consecutive days, followed by a 7-day
washout period and then active tDCS for 5 consecutive
days. Clinical pain assessment and 1H-MRS testing
were performed at baseline, the week following the sham
tDCS trial, and the week following the active tDCS trial.
Results. Clinical pain scores decreased signifi-
cantly between the baseline and active tDCS time points
(P 0.04). Levels of glutamate glutamine (Glx) in the
anterior cingulate were significantly lower at the post–
active tDCS assessment compared with the post–sham
tDCS assessment (P  0.013), and the decrease in
Glx levels in the thalami between these time points
approached significance (P  0.056). From baseline
to the post–sham tDCS assessment, levels of
N-acetylaspartate (NAA) in the posterior insula in-
creased significantly (P  0.015). There was a trend
toward increased levels of -aminobutyric acid (GABA)
in the anterior insula after active tDCS, compared with
baseline (P  0.064). Baseline anterior cingulate Glx
levels correlated significantly with changes in pain
score, both for the time period from baseline to sham
tDCS (1  1.31, P < 0.001) and for the time period
from baseline to active tDCS (1  1.87, P < 0.001).
Conclusion. The present findings suggest that
GABA, Glx, and NAA play an important role in the
pathophysiology of FM and its modulation by tDCS.
Chronic pain impacts 100 million people in the
US, with annual costs exceeding 635 billion dollars (1).
Fibromyalgia (FM) is considered the prototypical cen-
tral pain syndrome, and emerging data suggest that
patients with FM have central nervous system alterations
(2–4). Despite the availability of multiple treatments for
this condition, many FM patients still report significant
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unresolved pain and disability. A significant limitation to
evaluating potential interventions for chronic pain syn-
dromes, including FM, is the lack of an objective marker
of pain. There has been significant interest in using
neuroimaging methods, such as proton magnetic reso-
nance spectroscopy (1H-MRS), to develop an objective
test of pain. 1H-MRS can be used to measure levels of
brain metabolites, including -aminobutyric acid
(GABA) (the brain’s major inhibitory neurotransmit-
ter), Glx (a combined marker of glutamine and gluta-
mate, the latter being the brain’s major excitatory neu-
rotransmitter), and N-acetylaspartate (NAA) (thought
to be a measure of neuronal integrity). Our group has
reported increased levels of Glx in the posterior insula,
which is responsible for the graded sensory processing of
pain (5,6), in patients with FM. We have also reported
decreased levels of GABA in the anterior insula, which
is important in the emotional processing and affective
aspects of pain (6,7), in FM patients. Lower NAA levels
within the hippocampus in the setting of FM have also
been described (8).
One potential treatment for FM is transcranial
direct current stimulation (tDCS), a brain-stimulating
procedure that uses noninvasive weak direct current
applied to the scalp. In FM as well as other pain
conditions, tDCS has been shown to modulate experi-
mental and clinical pain. Specifically, it has been found
to improve pain symptoms in FM (9,10). Anodal stimu-
lation from tDCS has been demonstrated to increase
cortical excitability, which is postulated to mitigate pain
symptoms through indirect effects on pain processing
regions in the brain (9). However, the mechanisms
underlying the efficacy of tDCS in chronic pain are not
well understood, and trials assessing its effects on
chronic pain have yielded inconsistent results (11). Our
objective in the present study was to explore the under-
lying neurochemical action of tDCS in the brain in FM,
using 1H-MRS.
PATIENTS AND METHODS
Trial design. This longitudinal trial had 3 phases: 1) a
baseline period to measure pain levels and perform 1H-MRS,
2) 5 consecutive days of sham tDCS, followed by pain as-
sessment and 1H-MRS, and 3) 5 consecutive days of active
tDCS, followed by pain assessment and 1H-MRS. The second
and third phases were separated by a 7-day washout period.
Randomization was not performed given the presence of sig-
nificant carryover effects with active tDCS (12) and the small
sample size.
Patients. Thirteen female subjects (mean  SD age
47.6  10.6 years [range 27–64]) were recruited for this study.
Twelve of the subjects completed the entire protocol; 1
dropped out after the baseline pain assessment/1H-MRS. The
first 2 of the 12 subjects did not have GABA data collected at
the baseline time point due to protocol change, but did have
Glx and NAA data collected. All subjects met the American
College of Rheumatology 1990 criteria for FM (13) with a
symptom duration of at least 1 year, had reported continued
presence of pain on 50% of days, and were willing to refrain
from introducing any new medications or treatments for
control of FM symptoms during the study. All subjects were
right-handed and had a body mass index of 36 kg/m2. We
excluded FM patients who had a history of coexisting auto-
immune or chronic inflammatory disease that causes pain (e.g.,
rheumatoid arthritis, systemic lupus erythematosus, or inflam-
matory bowel disease), who had a history of substance abuse or
were currently taking opiates, or who had a history of severe
psychiatric illness (e.g., current major depression and schizo-
phrenia). FM patients who were pregnant, breastfeeding, or
participating in other therapeutic clinical trials were also
excluded. The study was approved by the University of Mich-
igan Institutional Review Board. All subjects provided written
informed written consent.
Clinical assessments. In clinical assessments, the pa-
tients were asked to refer to the “average” symptoms
experienced/perceived during 3 time periods: the week prior to
the initial 1H-MRS, the period between first-trial initiation
(sham tDCS) and second 1H-MRS, and the period between
second-trial initiation (active tDCS) and final 1H-MRS. Pain
intensity was measured using a 10-point visual analog scale
(VAS), with 0 representing no pain and 10 representing the
worst possible pain. Affective state was assessed using the
positive and negative affect scores from the Positive and
Negative Affect Schedule (PANAS) (14). Pain discrimination
and subjective pain experience were evaluated using the long-
form McGill Pain Questionnaire (15) for the baseline visit and
the short-form McGill Pain Questionnaire (16) for the post–
sham tDCS and post–active tDCS visits.
Transcranial direct current stimulation. For both the
sham and active tDCS sessions, the anode electrode was placed
on the scalp overlying the left motor cortex and the cathode
electrode was placed on the scalp overlying the right supraor-
bital cortex. During the active tDCS sessions, 2 mA of trans-
cranial direct current stimulation was applied for 20 minutes.
For the sham tDCS, the current was applied for only 30
seconds at the beginning and end of the session. A 30-second
application of current is considered a method of sham stimu-
lation, as sensations arising from tDCS treatment occur mostly
at the beginning and end of application (17). Individual
measurements determined the anatomic location for place-
ment of the electrodes using the convention of electroenceph-
alography 10/20 system. Placement of the electrodes was
performed by the same operators (AFD and TDN) for all
patients.
Proton magnetic resonance spectroscopy. A Philips
Ingenia 3T system with a 15-channel receive head coil was used
for imaging acquisition. Voxel placement was performed using
a 3-dimensional magnetization-prepared rapid gradient-echo
sequence with 0.9-mm3 isotropic voxel resolution. 1H-MRS
spectra were collected with 3.0 cm  2.0 cm  3.0 cm volumes
from the right anterior insula, right posterior insula, and
anterior cingulate and a 2.0 cm 4.0 cm 2.2 cm volume from
bilateral thalami (data available from the corresponding au-
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thor upon request). These regions were chosen a priori given
their importance in pain perception processing, based on our
prior work which has demonstrated significant alterations of
GABA and/or Glx in the right insula and anterior cingulate of
FM patients, and because they have also been shown, using
other advanced neuroimaging techniques, to be altered under
conditions of chronic pain (3,5,7,18).
Single-voxel point-resolved spectroscopy (PRESS)
(repetition time [TR]/echo time [TE] 2,000/35 msec) was
performed using VAPOR (variable pulse power and optimized
relaxation) water suppression with 32 averages to measure Glx
and NAA levels. A Mescher-Garwood point-resolved spectros-
copy (MEGA-PRESS) experiment, which edits out the over-
lapping creatine peak at 3.0 parts per million (19), was
performed to measure GABA levels. The MEGA-PRESS
experiment was performed using the following parameters: TE
68 msec (TE1 15 msec, TE2 53 msec), TR 1.8 seconds, 256
transients of 2,000 data points, spectral width 2 kHz, frequency
selective editing pulses (14 msec) applied at 1.9 ppm (on) and
7.46 ppm (off). Amplitude-modulated pulse GTST1203
(length 7 msec, bandwidth 1.2 kHz) was used for refocusing.
Conventional PRESS spectroscopy data were analyzed with
LCModel. MEGA-PRESS spectroscopy data were analyzed
using MatLab in-house postprocessing software to fit Gaussian
curves to the GABA and inverted NAA peaks. The absolute
NAA concentration, as generated from LCModel analysis of
the PRESS data, was multiplied by the GABA:NAA ratio as
generated from the MatLab analysis to determine the concen-
tration of GABA (in arbitrary institutional units [AIU]). There
was inadequate signal-to-noise ratio for the GABA spectra in
the anterior cingulate and anterior insula in 1–2 subjects, and
in the thalami in 2–3 subjects, at each of the trial phases.
Statistical analysis. Stata version 11 was used for
statistical analysis. The significance of changes in brain metab-
olite levels in the different brain regions between baseline and
sham tDCS, between baseline and active tDCS, and between
sham tDCS and active tDCS was determined by paired 2-tailed
t-test. We also correlated the scores from the VAS scale and
the McGill and PANAS questionnaires at each of the time
points with the respective brain metabolite levels from the
different voxel locations. Linear regression analysis was per-
formed to assess correlations between brain metabolite values
at baseline and changes in the pain score from baseline to sham
tDCS and from baseline to active tDCS. P values less than 0.05
were considered significant.
RESULTS
We observed substantial longitudinal changes in
clinical pain scores, with a significant decrease in the
VAS pain score from baseline to active tDCS (P  0.04)
(Table 1). There was a trend toward a decrease in the
Table 1. Clinical scores and correlations between clinical scores and metabolite levels in various brain
regions in the 12 patients with fibromyalgia*
Baseline Post–sham tDCS Post–active tDCS
VAS pain score
Mean  SD 5.1 2.3 4.1  2.1 3.3  2.8†
Correlation (r)
– With ACC GABA level 0.74‡ NS NS
– With post. ins. NAA level NS NS 0.60§
– With thalamus GABA level 0.75§ NS NS
– With thalamus NAA level NS 0.75‡ NS
MPQ score (long form), mean  SEM 22.9  14.9 – –
MPQ score (short form), mean  SEM – 18.7 12.5 19.3  15.3
PANAS score
Mean  SD 19.8 6.0 17.8  5.5 16.1  6.4
Correlation (r)
– With ant. ins. Glx level 0.87‡ NS NS
– With ant. ins. NAA level 0.68§ NS NS
– With ant. ins. GABA level NS NS 0.71§
– With post. ins. Glx level 0.78‡ NS NS
– With post. ins. NAA level NS NS 0.61§
– With thalamus GABA level NS 0.78§ NS
PANAS score 14.3 3.4 15.4  5.5 12.7  3.6¶
– With post. ins. GABA level NS NS 0.65§
– With post. ins. NAA level NS NS 0.63§
– With thalamus GABA level NS 0.79‡ NS
* tDCS  transcranial direct current stimulation; VAS  visual analog scale; ACC  anterior cingulate;
GABA  –aminobutryic acid; NS  not significant; post. ins.  posterior insula; NAA  N-
acetylaspartate; MPQ  McGill Pain Questionnaire; PANAS  Positive and Negative Affect Schedule;
ant. ins.  anterior insula; Glx  combined glutamate  glutamine.
† P  0.04 versus baseline.
‡ P  0.01.
§ P  0.05.
¶ P  0.02 versus baseline.
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VAS score from baseline to sham tDCS (P  0.10).
Between sham tDCS and active tDCS the VAS pain
score did not change significantly (P  0.16). The
PANAS score decreased significantly from baseline to
active tDCS (P  0.02). There were no additional
significant changes in the PANAS score for the different
time point comparisons. Between sham tDCS and active
tDCS there was a significant decrease in Glx levels in the
anterior cingulate (P  0.013) and a trend toward a
decrease in Glx levels in the thalamus (P  0.056)
(Figure 1). From baseline to active tDCS there was a
trend toward an increase in GABA levels in the anterior
insula (P  0.064). In addition, NAA levels in the
posterior insula increased significantly from baseline
(mean  SD 7.68  0.45 AIU) to sham tDCS (8.24 
0.58 AIU) (P  0.015).
There were a number of moderate-to-strong cor-
relations between brain metabolite levels and the clinical
rating scales. Higher levels of GABA and NAA and
lower levels of Glx from the prescribed brain region
voxels were associated with better clinical pain and
affect scores (Table 1). Linear regression analysis re-
vealed that Glx levels in the anterior cingulate at base-
line correlated significantly with changes in the VAS
pain score between baseline and sham tDCS (1  1.31,
P  0.001) and between baseline and active tDCS (1 
1.87, P  0.001) (Figure 2), with higher levels of Glx in
the anterior cingulate at baseline associated with greater
reductions in clinical pain following both the sham and
active treatment phases.
DISCUSSION
In the present longitudinal trial we observed that
the anterior cingulate was the region most affected by
tDCS treatment in FM patients, with a significant de-
crease in Glx levels. Furthermore, we found that patients
with higher levels of Glx in the anterior cingulate at
baseline tended to show a greater degree of improve-
ment in clinical pain after both the sham and the tDCS
treatments. The anterior cingulate is a key component in
the brain’s pain modulating regions and is also involved
in the emotional processing of pain (6). Its structure and
function have been found to be altered in chronic pain
states; specifically, focal atrophy and reduced connectiv-
ity in the rostral anterior cingulate have been described
(12,18). Furthermore, the rostral anterior cingulate has
been shown to be an important region for descending
inhibition of pain (12). Our findings suggest that “nor-
malization” of Glx in the anterior cingulate may have an
important role in the mechanism of action of tDCS for
the treatment of fibromyalgia. In addition, the strength
of the regression coefficient and high level of signifi-
cance between Glx levels in the anterior cingulate and
Figure 1. Transcranial direct current stimulation (tDCS) electrode placement and proton magnetic resonance spectroscopy results. A, tDCS
montage, showing the anode placed over the primary motor cortex (M1) and the cathode over the contralateral supraorbital cortex. B and C,
Significantly decreased levels of Glx (glutamate  glutamine) in the anterior cingulate (ACC) following active tDCS treatment (B), with a trend
toward a significant decrease in levels of Glx in the thalamus (C). D, Trend toward a significant increase in levels of -aminobutyric acid (GABA)
in the anterior insula after sham and active tDCS treatments. Each symbol represents an individual fibromyalgia patient. AIU  arbitrary
institutional units.
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clinical pain improvement suggest that 1H-MRS may
prove to be a clinically useful predictor of tDCS efficacy
in FM. We speculate that the higher regression coeffi-
cient for the correlation of baseline Glx levels with the
change in pain score after active tDCS (1  1.87)
relative to the change in pain score after sham tDCS
(1  1.31) may reflect additive placebo response to the
tDCS treatment.
The present findings complement our results in a
study of pregabalin treatment, which demonstrated that
baseline Glx levels were associated with pain response,
albeit in a different brain region (3). Increases in Glx
and NAA levels following tDCS stimulation have been
observed in the parietal cortex underneath the anode
(20), suggesting that tDCS locally increases glutamater-
gic activity and neuronal metabolism.
There was a trend toward decreased levels of Glx
in the thalamus following tDCS treatment. The thala-
mus, which is a critical pain relay and processing center,
has exhibited alterations in blood flow, white matter
structure, and connectivity in FM (21). We also observed
a trend toward increased levels of GABA in the anterior
insula following tDCS treatment, complementing our
earlier findings of reduced levels of GABA in FM
patients as compared to healthy controls (7). The pain
processing regions of the brain also demonstrated sig-
nificant correlations between GABA and Glx levels and
clinical pain scores: patients with higher levels of GABA
and lower levels of Glx had lower levels of pain intensity
(as measured by VAS) and negative affect (as measured
by PANAS) and higher levels of positive affect (as
measured by PANAS). These findings are consistent
with the notion that in FM there is an excitatory:
inhibitory ratio imbalance in the brain, resulting in
up-regulation of pain response/experience, as we have
previously proposed (5,7). Similar results were demon-
strated with regard to NAA levels in the anterior insula,
posterior insula, and thalami: patients with lower pain
scores, lower levels of negative affect, and higher levels
of positive affect tended to have higher levels of NAA.
Our findings, in addition to the increase in NAA levels
in the posterior insula that we observed following sham
tDCS treatment, suggest that neuronal integrity, as
measured by NAA, is important in chronic pain.
Limitations of the present study include the
relatively small number of subjects and lack of random-
ization. The large number of statistical comparisons
raises the possibility of Type I error. Furthermore, we
were unable to demonstrate a significant improvement
in clinical pain scores between the sham tDCS and active
tDCS time points, which may be due in part to placebo
response and the small sample size. We suggest that
given the exploratory nature of this study, subsequent
efforts be undertaken to confirm our results. In addition,
the GABA editing acquisition includes contributions
from macromolecules. GABA editing requires relatively
large voxel sizes and long time acquisitions, limiting the
number of potential brain regions to interrogate. For
future pain studies, it would be interesting to measure
local 1H-MRS changes underneath the anode.
In conclusion, our findings suggest that GABA,
Glx, and NAA play important roles in the pathophysi-
ology of chronic pain and its modulation by tDCS. There
were significant alterations in the levels of metabolites
Figure 2. Pretreatment levels of Glx in the anterior cingulate are
predictive of subsequent changes in clinical pain in fibromyalgia
patients receiving sham or active tDCS. Scatterplots show baseline
levels of Glx versus posttreatment changes in clinical pain (rated on a
visual analog scale) following sham tDCS () and active tDCS ().
Patients with higher levels of Glx in the anterior cingulate at baseline
had greater reductions in clinical pain following both sham and active
tDCS. See Figure 1 for definitions.
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for various pain centers in the brain following both the
sham and active tDCS phases of the present trial.
Furthermore, baseline Glx levels in the anterior cingu-
late predicted response to treatment. These findings
encourage further work to pursue targeted therapy with
tDCS and other noninvasive brain stimulation modali-
ties in FM and other chronic pain conditions.
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